Whether they have worked in the healthcare industry or not, most understand the sensitivity and importance of the patient information that is stored by healthcare groups and systems. Healthcare providers… Read More »Healthcare and Ransomware
May 22, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking Twice that… Read More »Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
May 15, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Total Voting Rights Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical… Read More »Posting of Annual Report & Notice of AGM – Total Voting Rights
Discover how implementing managed IT services can revolutionize the operations of CPA firms, ensuring cybersecurity, enhancing unified communications, and ensuring compliance with industry regulations.
19 April 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX),… Read More »Preliminary Results for the Year Ended 31 December 2023
Why Regular Cleaning is Essential Regular cleaning is essential for maintaining the performance and longevity of your computer system. Over time, dust, dirt, and debris can accumulate on the various… Read More »Keep Your Computer Sparkling Clean
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option Closes acquisition of exclusive, worldwide license to Tolimidone, Phase… Read More »Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing… Read More »Interim results for the six months ended 30 June 2023
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline of products aimed… Read More »Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
